Original Article
The effect of atorvastatin combined with insulin glargine on renal function in patients with early diabetic nephropathy
Shen Haiyan, Li Xiangdong, Li Yi, Zhao Ming, Zhai Ying, Guo Bohui, Chen Qingjuan
Published 2020-02-05
Cite as Chin J Postgrad Med, 2020,43(02): 118-121. DOI: 10.3760/cma.j.issn.1673-4904.2020.02.005
Abstract
ObjectiveTo observe the effect of atorvastatin combined with insulin glargine on renal function in patients with early diabetic nephropathy.
MethodsFrom January 2016 to March 2019, 100 patients with early diabetic nephropathy admitted to Hanzhong 3201 Hospital Affiliated with Xi′an Jiaotong University Medical School were selected as subjects. According to the random number table, patients were divided into control group and observation group, with 50 cases in each group. All patients underwent diet control, blood pressure control and symptomatic treatment. Patients in the control group were treated with insulin glargine to control blood glucose. Patients in observation group were given atorvastatin on this basis. After 16 weeks of treatment, the therapeutic effects of the two groups were observed, as well as the change in urinary albumin excretion rate (UAER), serum creatinine (Scr), C-reactive protein (CRP), total cholesterol (TC), and triglyceride (TG). Adverse reactions were observed during treatment in both groups.
ResultsAfter treatment, the levels of UAER, Scr, CRP, TC and TG of the two groups were lower than those before treatment, and the above indexes of the observation group were lower than those of the control group. The difference were statistically significant (P<0.05). During the treatment period, the incidence of adverse reactions in control group and observation group was 4.00%(2/50) and 12.00%(6/50), and there was no significant difference (P>0.05).
ConclusionsAtorvastatin combined with insulin glargine in the treatment of early diabetic nephropathy can effectively reduce the levels of UAER, Scr, CRP, TC and TG, and has good safety.
Key words:
Diabetic nephropathy; Atorvastatin; Insulin glargine; Treatment outcome; Renal function
Contributor Information
Shen Haiyan
Department of Nephrology, Hanzhong 3201 Hospital Affiliated of Xi′an Jiaotong University Medical School, Shaanxi Hanzhong 723000, China
Li Xiangdong
Department of Nephrology, Hanzhong 3201 Hospital Affiliated of Xi′an Jiaotong University Medical School, Shaanxi Hanzhong 723000, China
Li Yi
Department of Nephrology, Hanzhong 3201 Hospital Affiliated of Xi′an Jiaotong University Medical School, Shaanxi Hanzhong 723000, China
Zhao Ming
Department of Nephrology, Hanzhong 3201 Hospital Affiliated of Xi′an Jiaotong University Medical School, Shaanxi Hanzhong 723000, China
Zhai Ying
Department of Nephrology, Hanzhong 3201 Hospital Affiliated of Xi′an Jiaotong University Medical School, Shaanxi Hanzhong 723000, China
Guo Bohui
Department of Nephrology, Hanzhong 3201 Hospital Affiliated of Xi′an Jiaotong University Medical School, Shaanxi Hanzhong 723000, China
Chen Qingjuan
Department of Oncology, Xianyang Central Hospital, Shaanxi Xianyang 712000, China
